<?xml version='1.0' encoding='utf-8'?>
<document id="17944992"><sentence text="Pyrazolinone analgesics prevent the antiplatelet effect of aspirin and preserve human platelet thromboxane synthesis."><entity charOffset="0-12" id="DDI-PubMed.17944992.s1.e0" text="Pyrazolinone" /><entity charOffset="59-66" id="DDI-PubMed.17944992.s1.e1" text="aspirin" /><entity charOffset="95-106" id="DDI-PubMed.17944992.s1.e2" text="thromboxane" /><pair ddi="false" e1="DDI-PubMed.17944992.s1.e0" e2="DDI-PubMed.17944992.s1.e0" /><pair ddi="false" e1="DDI-PubMed.17944992.s1.e0" e2="DDI-PubMed.17944992.s1.e1" /><pair ddi="false" e1="DDI-PubMed.17944992.s1.e0" e2="DDI-PubMed.17944992.s1.e2" /><pair ddi="false" e1="DDI-PubMed.17944992.s1.e1" e2="DDI-PubMed.17944992.s1.e1" /><pair ddi="false" e1="DDI-PubMed.17944992.s1.e1" e2="DDI-PubMed.17944992.s1.e2" /></sentence><sentence text="Anti-inflammatory analgesics, including ibuprofen and naproxen, are known to interfere with the antiplatelet effect of aspirin, presumably as a result of a drug-drug interaction at the level of platelet cyclooxygenase-1 (COX-1)"><entity charOffset="40-49" id="DDI-PubMed.17944992.s2.e0" text="ibuprofen" /><entity charOffset="54-62" id="DDI-PubMed.17944992.s2.e1" text="naproxen" /><entity charOffset="119-126" id="DDI-PubMed.17944992.s2.e2" text="aspirin" /><pair ddi="false" e1="DDI-PubMed.17944992.s2.e0" e2="DDI-PubMed.17944992.s2.e0" /><pair ddi="false" e1="DDI-PubMed.17944992.s2.e0" e2="DDI-PubMed.17944992.s2.e1" /><pair ddi="false" e1="DDI-PubMed.17944992.s2.e0" e2="DDI-PubMed.17944992.s2.e2" /><pair ddi="false" e1="DDI-PubMed.17944992.s2.e1" e2="DDI-PubMed.17944992.s2.e1" /><pair ddi="false" e1="DDI-PubMed.17944992.s2.e1" e2="DDI-PubMed.17944992.s2.e2" /></sentence><sentence text="" /><sentence text="We studied whether dipyrone, which has recently been reported to inhibit COX isoforms by a mechanism different from conventional non-steroidal anti-inflammatory drugs (NSAIDs), also interferes with the antiplatelet effect of aspirin"><entity charOffset="19-27" id="DDI-PubMed.17944992.s4.e0" text="dipyrone" /><entity charOffset="225-232" id="DDI-PubMed.17944992.s4.e1" text="aspirin" /><pair ddi="false" e1="DDI-PubMed.17944992.s4.e0" e2="DDI-PubMed.17944992.s4.e0" /><pair ddi="false" e1="DDI-PubMed.17944992.s4.e0" e2="DDI-PubMed.17944992.s4.e1" /></sentence><sentence text="" /><sentence text="Arachidonic acid- and collagen-induced aggregation, as well as thromboxane formation, were measured in human platelet-rich plasma"><entity charOffset="63-74" id="DDI-PubMed.17944992.s6.e0" text="thromboxane" /></sentence><sentence text=" Platelet P-selectin expression was determined by flow cytometry and cell-free COX enzyme activity was quantified by luminol-enhanced luminescence of human platelet microsomes" /><sentence text=" In addition, computerized docking was performed based on the crystal structure of COX-1" /><sentence text="" /><sentence text="4-Methylaminoantipyrine (MAA), the active metabolite of dipyrone, largely attenuated or even completely abolished the inhibition of arachidonic acid-induced platelet aggregation, thromboxane formation and P-selectin expression by aspirin"><entity charOffset="0-23" id="DDI-PubMed.17944992.s10.e0" text="4-Methylaminoantipyrine" /><entity charOffset="25-28" id="DDI-PubMed.17944992.s10.e1" text="MAA" /><entity charOffset="56-64" id="DDI-PubMed.17944992.s10.e2" text="dipyrone" /><entity charOffset="132-148" id="DDI-PubMed.17944992.s10.e3" text="arachidonic acid" /><entity charOffset="179-190" id="DDI-PubMed.17944992.s10.e4" text="thromboxane" /><entity charOffset="230-237" id="DDI-PubMed.17944992.s10.e5" text="aspirin" /><pair ddi="false" e1="DDI-PubMed.17944992.s10.e0" e2="DDI-PubMed.17944992.s10.e0" /><pair ddi="false" e1="DDI-PubMed.17944992.s10.e0" e2="DDI-PubMed.17944992.s10.e1" /><pair ddi="false" e1="DDI-PubMed.17944992.s10.e0" e2="DDI-PubMed.17944992.s10.e2" /><pair ddi="false" e1="DDI-PubMed.17944992.s10.e0" e2="DDI-PubMed.17944992.s10.e3" /><pair ddi="false" e1="DDI-PubMed.17944992.s10.e0" e2="DDI-PubMed.17944992.s10.e4" /><pair ddi="false" e1="DDI-PubMed.17944992.s10.e0" e2="DDI-PubMed.17944992.s10.e5" /><pair ddi="false" e1="DDI-PubMed.17944992.s10.e1" e2="DDI-PubMed.17944992.s10.e1" /><pair ddi="false" e1="DDI-PubMed.17944992.s10.e1" e2="DDI-PubMed.17944992.s10.e2" /><pair ddi="false" e1="DDI-PubMed.17944992.s10.e1" e2="DDI-PubMed.17944992.s10.e3" /><pair ddi="false" e1="DDI-PubMed.17944992.s10.e1" e2="DDI-PubMed.17944992.s10.e4" /><pair ddi="false" e1="DDI-PubMed.17944992.s10.e1" e2="DDI-PubMed.17944992.s10.e5" /><pair ddi="false" e1="DDI-PubMed.17944992.s10.e2" e2="DDI-PubMed.17944992.s10.e2" /><pair ddi="false" e1="DDI-PubMed.17944992.s10.e2" e2="DDI-PubMed.17944992.s10.e3" /><pair ddi="false" e1="DDI-PubMed.17944992.s10.e2" e2="DDI-PubMed.17944992.s10.e4" /><pair ddi="false" e1="DDI-PubMed.17944992.s10.e2" e2="DDI-PubMed.17944992.s10.e5" /><pair ddi="false" e1="DDI-PubMed.17944992.s10.e3" e2="DDI-PubMed.17944992.s10.e3" /><pair ddi="false" e1="DDI-PubMed.17944992.s10.e3" e2="DDI-PubMed.17944992.s10.e4" /><pair ddi="false" e1="DDI-PubMed.17944992.s10.e3" e2="DDI-PubMed.17944992.s10.e5" /><pair ddi="false" e1="DDI-PubMed.17944992.s10.e4" e2="DDI-PubMed.17944992.s10.e4" /><pair ddi="false" e1="DDI-PubMed.17944992.s10.e4" e2="DDI-PubMed.17944992.s10.e5" /></sentence><sentence text=" Similar results were obtained for other pyrazolinones, as well as for the conventional NSAIDs ibuprofen and naproxen"><entity charOffset="41-54" id="DDI-PubMed.17944992.s11.e0" text="pyrazolinones" /><entity charOffset="95-104" id="DDI-PubMed.17944992.s11.e1" text="ibuprofen" /><entity charOffset="109-117" id="DDI-PubMed.17944992.s11.e2" text="naproxen" /><pair ddi="false" e1="DDI-PubMed.17944992.s11.e0" e2="DDI-PubMed.17944992.s11.e0" /><pair ddi="false" e1="DDI-PubMed.17944992.s11.e0" e2="DDI-PubMed.17944992.s11.e1" /><pair ddi="false" e1="DDI-PubMed.17944992.s11.e0" e2="DDI-PubMed.17944992.s11.e2" /><pair ddi="false" e1="DDI-PubMed.17944992.s11.e1" e2="DDI-PubMed.17944992.s11.e1" /><pair ddi="false" e1="DDI-PubMed.17944992.s11.e1" e2="DDI-PubMed.17944992.s11.e2" /></sentence><sentence text=" Moreover, MAA attenuated the effect of aspirin on COX activity of platelet microsomes, suggesting a competition with aspirin at the COX-1 enzyme"><entity charOffset="40-47" id="DDI-PubMed.17944992.s12.e0" text="aspirin" /><entity charOffset="118-125" id="DDI-PubMed.17944992.s12.e1" text="aspirin" /><entity charOffset="11-17" id="DDI-PubMed.17944992.s12.e2" text="MAA" /><pair ddi="false" e1="DDI-PubMed.17944992.s12.e2" e2="DDI-PubMed.17944992.s12.e2" /><pair ddi="false" e1="DDI-PubMed.17944992.s12.e2" e2="DDI-PubMed.17944992.s12.e0" /><pair ddi="false" e1="DDI-PubMed.17944992.s12.e2" e2="DDI-PubMed.17944992.s12.e1" /><pair ddi="false" e1="DDI-PubMed.17944992.s12.e0" e2="DDI-PubMed.17944992.s12.e0" /><pair ddi="false" e1="DDI-PubMed.17944992.s12.e0" e2="DDI-PubMed.17944992.s12.e1" /></sentence><sentence text=" This was confirmed by docking studies, which revealed that MAA forms a strong hydrogen bond with serine 530 within the COX-1, thereby preventing enzyme acetylation by aspirin"><entity charOffset="79-87" id="DDI-PubMed.17944992.s13.e0" text="hydrogen" /><entity charOffset="98-104" id="DDI-PubMed.17944992.s13.e1" text="serine" /><entity charOffset="168-175" id="DDI-PubMed.17944992.s13.e2" text="aspirin" /><entity charOffset="60-66" id="DDI-PubMed.17944992.s13.e3" text="MAA" /><pair ddi="false" e1="DDI-PubMed.17944992.s13.e3" e2="DDI-PubMed.17944992.s13.e3" /><pair ddi="false" e1="DDI-PubMed.17944992.s13.e3" e2="DDI-PubMed.17944992.s13.e0" /><pair ddi="false" e1="DDI-PubMed.17944992.s13.e3" e2="DDI-PubMed.17944992.s13.e1" /><pair ddi="false" e1="DDI-PubMed.17944992.s13.e3" e2="DDI-PubMed.17944992.s13.e2" /><pair ddi="false" e1="DDI-PubMed.17944992.s13.e0" e2="DDI-PubMed.17944992.s13.e0" /><pair ddi="false" e1="DDI-PubMed.17944992.s13.e0" e2="DDI-PubMed.17944992.s13.e1" /><pair ddi="false" e1="DDI-PubMed.17944992.s13.e0" e2="DDI-PubMed.17944992.s13.e2" /><pair ddi="false" e1="DDI-PubMed.17944992.s13.e1" e2="DDI-PubMed.17944992.s13.e1" /><pair ddi="false" e1="DDI-PubMed.17944992.s13.e1" e2="DDI-PubMed.17944992.s13.e2" /></sentence><sentence text="" /><sentence text="This study demonstrates for the first time that dipyrone and other pyrazolinones have a high potential to attenuate or prevent the antiplatelet effect of aspirin"><entity charOffset="48-56" id="DDI-PubMed.17944992.s15.e0" text="dipyrone" /><entity charOffset="67-80" id="DDI-PubMed.17944992.s15.e1" text="pyrazolinones" /><entity charOffset="154-161" id="DDI-PubMed.17944992.s15.e2" text="aspirin" /><pair ddi="false" e1="DDI-PubMed.17944992.s15.e0" e2="DDI-PubMed.17944992.s15.e0" /><pair ddi="false" e1="DDI-PubMed.17944992.s15.e0" e2="DDI-PubMed.17944992.s15.e1" /><pair ddi="false" e1="DDI-PubMed.17944992.s15.e0" e2="DDI-PubMed.17944992.s15.e2" /><pair ddi="false" e1="DDI-PubMed.17944992.s15.e1" e2="DDI-PubMed.17944992.s15.e1" /><pair ddi="false" e1="DDI-PubMed.17944992.s15.e1" e2="DDI-PubMed.17944992.s15.e2" /></sentence><sentence text=" This should be considered if pyrazolinone analgesics are administered to patients with cardiovascular disease requiring antiplatelet aspirin therapy"><entity charOffset="30-42" id="DDI-PubMed.17944992.s16.e0" text="pyrazolinone" /><entity charOffset="134-141" id="DDI-PubMed.17944992.s16.e1" text="aspirin" /><pair ddi="false" e1="DDI-PubMed.17944992.s16.e0" e2="DDI-PubMed.17944992.s16.e0" /><pair ddi="false" e1="DDI-PubMed.17944992.s16.e0" e2="DDI-PubMed.17944992.s16.e1" /></sentence><sentence text="" /></document>